

Oncology Today with Dr Neil Love: Novel Induction and Maintenance Strategies in Acute Myeloid Leukemia Edition (Interview Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following outcomes was demonstrated in the Phase III QUAZAR AML-001 trial evaluating oral azacitidine (CC-486) in combination with best supportive care (BSC) versus placebo with BSC as maintenance therapy for patients with acute myeloid leukemia (AML) in complete remission after induction therapy with or without consolidation chemotherapy?**
 - a. No statistically significant improvement in overall survival (OS) or relapse-free survival (RFS) between arms
 - b. A statistically significant improvement in OS but not RFS with CC-486
 - c. A statistically significant improvement in RFS but not OS with CC-486
 - d. A statistically significant improvement in OS and RFS with CC-486
- 2. A randomized Phase II trial evaluating CPX-351 versus conventional 7 + 3 therapy (cytarabine and daunorubicin) for patients aged 60 to 75 years with previously untreated secondary AML demonstrated which of the following outcomes?**
 - a. A significantly improved benefit with the conventional 7 + 3 regimen compared to CPX-351
 - b. A significantly improved benefit with CPX-351 compared to the conventional 7 + 3 regimen
 - c. A similar treatment benefit with CPX-351 compared to the conventional 7 + 3 regimen
- 3. Adverse events commonly observed with CPX-351 therapy for patients with newly diagnosed secondary AML include which of the following?**
 - a. Significant alopecia only
 - b. Delayed hematologic recovery only
 - c. Both significant alopecia and delayed hematologic recovery
- 4. Which of the following drug types best describes the mechanism of action of glasdegib?**
 - a. FLT3 inhibitor
 - b. Bcl-2 inhibitor
 - c. Hedgehog pathway inhibitor